Jaguar Health Sets 1-for-15 Reverse Split Effective September 17
JAGX is trading near its 52-week low of $0.292 (0.8% below the low) on elevated volume (2.1× avg).
Summary
Jaguar Health will execute a 1-for-15 reverse stock split effective September 17, 2026, to support Nasdaq listing compliance. The split was approved by stockholders in April 2026 and finalizes the ratio and effective date.
Key Events · Corporate Governance and Compliance · JAGX
-
1-for-15 Reverse Split Finalized
Board selected a 1-for-15 ratio from the previously approved 1-for-15 to 1-for-150 range, effective September 17, 2026 at 12:01 am ET.
-
Nasdaq Compliance Objective
The reverse split is intended to support compliance with Nasdaq's minimum bid price listing standard, as the stock trades near its 52-week low of $0.2916.
-
Share Count and Price Adjustment
Every 15 shares will be reclassified into 1 share, proportionally reducing outstanding shares and increasing the per-share price without changing total market value.
-
New CUSIP and Exchange Agent
New CUSIP number 47010C 854 assigned; Equiniti Trust Company, LLC will act as exchange agent for the split.
Analysis · JAGX · Life Sciences
Jaguar Health finalized the terms of its previously approved reverse stock split, selecting a 1-for-15 ratio and setting the effective date for September 17, 2026. The move is aimed at regaining compliance with Nasdaq's minimum bid price requirement, a critical step for a company trading near its 52-week low with a going concern warning. While the split itself does not change the company's market value, it reduces the share count and proportionally increases the per-share price, which could help avoid delisting but also signals the company's ongoing struggle to maintain its listing.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.29 to $85.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.